Wuxi Biologics (cayman) Inc. · HKEX:2269
Wuxi Biologics (cayman) — WuXi Biologics — Non-Deal Roadshow (May 2025)
11 slides from Wuxi Biologics (cayman)'s roadshow presentation, May 2025
Slide 1: Our CRDMO Business Model Explained
Our CRDMO Business Model Explained May 2025 Stock Code: 2269.HK
Slide 2: CRDMO Business Model
CRDMO Business Model CRDMO Research = Fully Integrated Project (FIP) + CRO FIP supports clients from initial concept through IND submission, • The CRDMO business model provides integrated, end-to-end R seamlessly integrating with CMC & downstream process development. Leveraging its proprietary techn
Slide 3: CRDMO Business Model Supports Long-term Growth
CRDMO Business Model Supports Long-term Growth Biologics Development Typical Process Duration Typical Revenue Our Three Long-Term Growth Curves Pre-IND Upfront payment up to R+D+M Through $40m+/program Research molecule’s Milestone fee up to $200m+ life cycle /program Royalty fee up to 10% of drug s
Slide 4: New Projects Added in 2024 Reflecting Recovery of Global Biotech
151 New Projects Added in 2024 Reflecting Recovery of Global Biotech & Robust Business Trend • Leveraging its robust R&D capabilities and WuXiBodyTM OMT Platform ADC Platform SDArBodYTM strong execution, the Company continued to enable customers while advancing our • “Follow and Win the Molecule” st
Slide 5: Research Services Have Enabled 50+ Programs for Global Clients to Date
Research Services Have Enabled 50+ Programs for Global Clients to Date R Project Distribution by Phase (as of Feb’25) CMO e.g. CStone PD-L1, Gloria PD-1; low-single digit royalty Phase III e.g. RCUS/GILD PD-1; royalty 7 - 10% of drug sales 45%+ of programs are sponsored by ex-China clients Phase II
Slide 6: Revenue Potential for RDM from a typical program
Revenue Potential for RDM from a typical program Most programs CD3 TCEs programs Revenue GPM% Revenue GPM% R 80%+ 80%+ Upfront up to $30+m up to $40+m (1x) Milestone up to $200m+ up to $200m+ (cumulative) Royalties up to $100m/yr for up to $100m/yr for (recurring) every $1b sales every $1b sales flu
Slide 7: Accelerating IND Timelines: 9-month Packages with GMP Materials Produced in North America
Accelerating IND Timelines: 9-month Packages with GMP Materials Produced in North America 9-Month from DNA to IND Accelerated Timeline for mAb (GMP DS & DP mfg. in Cranbury, NJ) ▪ Leveraging deep PD expertise from China team ▪ MCB and GMP DS/DP all stored in US for future resupply ▪ One-stop service
Slide 8: FDA Plan to Phase Out Animal Testing Requirement for mAb Potentially a Tailwind
FDA Plan to Phase Out Animal Testing Requirement for mAb Potentially a Tailwind Animal testing requirement in Toxicology studies is costly & could easily take 6+ months FDA Announces Plan to Phase Out • Exploratory toxicology (pilot studies): 1+ months Animal Testing Requirement for • GLP-compliant
Slide 9: Single-Use Technology Scaled Out to Large Batch Sizes Comparable to Stainless Steel Tanks
Single-Use Technology Scaled Out to Large Batch Sizes Comparable to Stainless Steel Tanks 120 Number of Successful Scale Out Batches (by year) Number of Successful Scale Out Batches (by scale) 100 Scale out batches 16,000L, 5, 2% 4,000L, 6, 2% 80 77 77 66 6,000L, 82, 27% 60 41 40 20 16 17 8,000L, 12
Slide 10: Case 1: Successful Scale-out for a Win-the-Molecule Project to 10,000L
Case 1: Successful Scale-out for a Win-the-Molecule Project to 10,000L Technical strength & speed enabled 10,000 L scale-out & FDA approval • WuXi Bio’s rapid tech transfer, process optimization, and regulatory expertise supported seamless scale-out to 10,000L using 5 x 2,000L bioreactors (comparabl
Slide 11: Case 2: Successful Scale-out from 2,000L to 12,000L at Higher Titer
Case 2: Successful Scale-out from 2,000L to 12,000L at Higher Titer Scale-out & high-titer process enabled FDA approval with improved product COGS • Partnering from IND to launch, WuXi Bio supported 3 generations of process development, culminating in FDA approval in 2025 for Process 3.0 o Process 3